Expert group consensus regarding the place of ivabradine in therapy optimisation in patients with chronic heart failure

Marcin Barylski; Małgorzata Lelonek; Artur Mamcarz; Agnieszka Mastalerz-Migas

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

1/2019
vol. 5

Send email

Copy url:

abstract:

Review paper

Expert group consensus regarding the place of ivabradine in therapy optimisation in patients with chronic heart failure

Marcin Barylski

,

Małgorzata Lelonek

,

Artur Mamcarz

,

Agnieszka Mastalerz-Migas

Online publish date: 2019/03/20

View full text Get citation

Accelerated heart rate is a risk factor of general and cardiovascular mortality in different populations. The classical treatment to achieve heart rate reduction by β-blockers and calcium channel antagonists from the group of non-dihydropyridines (verapamil and diltiazem) is often limited by contraindications or adverse reactions. Ivabradine is a unique, modern drug, the mechanism of action of which is blocking the If current in the sinoatrial node. This translates into a reduction in heart rate – a parameter associated with poor prognosis in patients with heart failure. The following document contains the opinion of an expert group summarising current knowledge on ivabradine and its use in the population of patients with heart failure.

keywords:

Expert group consensus regarding the place of ivabradine in therapy optimisation in patients with chronic heart failure

Marcin Barylski , Małgorzata Lelonek , Artur Mamcarz , Agnieszka Mastalerz-Migas

therapy optimisation, heart failure, ivabradine

Marcin Barylski

,

Małgorzata Lelonek

,

Artur Mamcarz

,

Agnieszka Mastalerz-Migas